APA (7th ed.) Citation

Kiełczyńska, A., Gilant, E., Pawiński, T., Szlaska, I., Buś-Kwaśnik, K., Pesta, E., . . . Kwiatkowska, B. (2025). Development and Validation of LC-MS/MS Method for Nintedanib and BIBF 1202 Monitoring in Plasma of Patients with Progressive Pulmonary Fibrosis Associated with Systemic Sclerosis. Pharmaceutics, 17(12), 1553. https://doi.org/10.3390/pharmaceutics17121553

Chicago Style (17th ed.) Citation

Kiełczyńska, Anna, Edyta Gilant, Tomasz Pawiński, Iwona Szlaska, Katarzyna Buś-Kwaśnik, Edyta Pesta, Daria Kuc, and Brygida Kwiatkowska. "Development and Validation of LC-MS/MS Method for Nintedanib and BIBF 1202 Monitoring in Plasma of Patients with Progressive Pulmonary Fibrosis Associated with Systemic Sclerosis." Pharmaceutics 17, no. 12 (2025): 1553. https://doi.org/10.3390/pharmaceutics17121553.

MLA (9th ed.) Citation

Kiełczyńska, Anna, et al. "Development and Validation of LC-MS/MS Method for Nintedanib and BIBF 1202 Monitoring in Plasma of Patients with Progressive Pulmonary Fibrosis Associated with Systemic Sclerosis." Pharmaceutics, vol. 17, no. 12, 2025, p. 1553, https://doi.org/10.3390/pharmaceutics17121553.